Why Route Matters for First-Pass Metabolism
After an oral victim drug is absorbed, it can be metabolized in the intestinal wall before reaching the portal vein, and again in the liver before entering systemic blood. These are distinct opportunities for first-pass loss. An inhibitor that changes intestinal CYP activity can therefore alter oral exposure without changing intravenous exposure. A hepatic inhibitor can affect both hepatic first-pass extraction and the systemic clearance encountered after drug reaches the circulation. Route-specific predictions help separate these effects, but only when absorption and disposition assumptions are made explicit.
The objective is not to infer a site from an oral exposure ratio alone. The same oral AUC change can arise from changed intestinal availability, hepatic availability, systemic clearance, or a combination. A PBPK model makes those components explicit; route comparisons then test whether the resulting pattern is consistent with the proposed site of action.
Exposure Equations and Their Assumptions
For a single oral dose with complete exposure measurement, linear pharmacokinetics, and dose-independent availability and clearance, the AUC is proportional to the amount reaching systemic circulation divided by systemic clearance. If \(CL\) denotes total systemic clearance, then:
These equations presume that the compared conditions have the same dose-normalized, linear disposition within each condition. At steady state, analogous AUC over a dosing interval can be used when the system is linear and the interval is fully observed. In comparing inhibitor and baseline conditions, assume also that the inhibitor does not change \(F_a\), unless a change in absorption is separately represented. A transporter effect, altered gastric emptying, or changed dissolution could violate that assumption.
For a fixed route and dose, define an exposure ratio as AUC with perpetrator divided by AUC at baseline. Subscripts 0 and 1 denote baseline and perpetrator conditions, respectively. If \(F_a\) is unchanged, the oral ratio is:
For intravenous dosing, there is no intestinal or hepatic first pass before systemic entry, so:
Thus, \(R_{\mathrm{po}}/R_{\mathrm{iv}}\) equals the change in presystemic availability \(F_gF_h\), provided \(F_a\) is unchanged and the same systemic disposition applies to both routes. This contrast does not by itself separate intestinal from hepatic first-pass change. That requires site-specific model predictions or additional evidence.
Worked Example: Isolating an Intestinal Contribution
Consider a hypothetical victim drug given as a 100 mg oral dose. A calibrated model predicts \(F_a=0.90\), \(F_{g,0}=0.60\), \(F_{h,0}=0.70\), and \(CL_0=10.0\) L/h. A perpetrator inhibits intestinal CYP, increasing \(F_g\) to 0.90, while \(F_a\), \(F_h\), and \(CL\) remain unchanged. Assume linear pharmacokinetics and complete AUC measurement.
At baseline, the oral AUC is:
With the perpetrator:
Therefore \(R_{\mathrm{po}}=5.67/3.78=1.50\). The model predicts a 50% increase in oral AUC. For the same hypothetical dose given intravenously, AUC is \(100/10.0=10.0\ \mathrm{mg\cdot h/L}\) in both conditions, so \(R_{\mathrm{iv}}=1.00\). Under the stated assumptions, an oral increase with no intravenous change is consistent with a gut-specific availability effect. It is not proof of intestinal CYP inhibition if other oral-specific processes could also change.
Connecting Hepatic Availability and Clearance
A hepatic effect is more subtle because hepatic extraction affects both the fraction escaping first pass and the clearance of drug in systemic blood. Under the well-stirred liver model, with hepatic blood flow \(Q_h\), unbound fraction in blood \(f_u\), and intrinsic hepatic clearance \(CL_{\mathrm{int,h}}\):
These relations assume a well-mixed liver, constant \(Q_h\), and the stated hepatic pathway as the clearance being represented. They show why changing \(F_h\) while arbitrarily holding hepatic clearance fixed may be inconsistent. For a drug whose only systemic clearance is hepatic, \(F_h/CL_h=1/(f_uCL_{\mathrm{int,h}})\). An inhibitor that lowers intrinsic clearance therefore increases both hepatic availability and intravenous AUC. If nonhepatic clearance is material, total \(CL\) must include it, and this simple identity no longer applies to total clearance.
Worked Example: A Hepatic CYP Effect on Both Routes
Suppose a hypothetical drug is cleared only by the liver. Let \(Q_h=90\) L/h and \(f_uCL_{\mathrm{int,h}}=38.57\) L/h at baseline. A hepatic inhibitor reduces \(f_uCL_{\mathrm{int,h}}\) to 10.0 L/h. Assume \(F_a=0.90\), \(F_g=0.60\), a 100 mg dose, and unchanged \(Q_h\), \(F_a\), and \(F_g\).
At baseline, the well-stirred model gives \(F_{h,0}=90/(90+38.57)=0.700\) (to three significant figures), and \(CL_{h,0}=90(1-0.700)=27.0\) L/h. With inhibition, \(F_{h,1}=90/(90+10.0)=0.900\), and \(CL_{h,1}=90(1-0.900)=9.00\) L/h.
The intravenous AUC ratio is \(R_{\mathrm{iv}}=27.0/9.00=3.00\). For the oral route, calculate the AUC in each condition:
The oral ratio is \(5.40/1.40=3.86\). It exceeds the intravenous ratio because hepatic inhibition increases \(F_h\) as well as reducing systemic hepatic clearance. The oral-to-intravenous ratio of ratios is \(3.86/3.00\approx1.29\), matching \(F_{h,1}/F_{h,0}=0.900/0.700\). This example depends on the liver being the only systemic clearance route; adding nonhepatic clearance would change the numerical relationship.
Using Matched Route Predictions to Diagnose Site
The most informative comparison uses the same victim, perpetrator condition, and model structure for both oral and intravenous administration. Compare predicted concentration-time profiles as well as dose-normalized AUC. Intravenous data bypass first-pass availability, so an IV exposure change points to altered systemic disposition (or an unmodeled change affecting IV disposition). An oral-only change suggests an absorption or first-pass contribution. A larger oral than IV change can reflect altered presystemic availability, but oral and IV comparisons alone cannot decide whether that availability change is intestinal or hepatic.
A practical PBPK diagnostic is to generate controlled model counterfactuals: first change intestinal CYP activity while holding hepatic activity at baseline; then change hepatic activity while holding intestinal activity at baseline; finally simulate both changes together. These are model experiments, not observations. Their interpretation depends on baseline calibration, plausible perpetrator concentrations at each enzyme site, and the assumed effect of inhibition on enzyme activity. The earlier material on modeling intestinal CYP3A inhibition by oral perpetrators supplies one component of this site-specific representation.
Check that the model reproduces baseline oral and, where available, IV concentration profiles and AUC under the intended dose and conditions.
Assess whether exposure changes occur for both routes or primarily after oral dosing, and check the full profiles rather than AUC alone.
Change gut CYP activity alone and liver CYP activity alone. Compare each predicted route pattern with the combined prediction and the evidence.
Investigate altered absorption, nonhepatic clearance, nonlinear kinetics, or mismatched dose conditions before assigning a site from route differences.
| Predicted pattern | Interpretation consistent with the pattern | Important qualification |
|---|---|---|
| Oral exposure changes; IV exposure is nearly unchanged | A predominantly presystemic or absorption-related effect | Does not uniquely identify intestinal CYP without ruling out other oral-specific changes. |
| Oral and IV exposure both change | A systemic disposition effect, potentially including hepatic CYP inhibition | Oral first-pass availability may also change; the IV result does not quantify it. |
| Oral change is larger than IV change | A systemic effect plus an additional presystemic availability change | The extra presystemic component may be gut, hepatic first pass, or both. |
Derivation, Limitations, and a Common Pitfall
The route-ratio result follows directly by dividing the oral exposure ratio by the IV exposure ratio. Under unchanged \(F_a\):
Thus the systemic clearance term cancels, but the two first-pass terms remain multiplied together. Without an independent estimate or model constraint on one of them, the route comparison identifies their product, not each factor separately. Furthermore, if \(F_a\) changes, the right-hand side acquires the factor \(F_{a,1}/F_{a,0}\). A route comparison is therefore a diagnostic contrast, not a universal site-identification procedure.
A common mistake is to attribute every oral exposure increase to intestinal inhibition because an oral dose passes through the gut. That reasoning ignores hepatic first-pass extraction and systemic clearance. For example, hepatic CYP inhibition can raise IV AUC by reducing systemic clearance and can raise oral AUC further by increasing \(F_h\). The correction is to compute or predict both route-specific changes, maintain a consistent hepatic model, and report which assumptions are needed for a site assignment.
Other failure modes include comparing non-dose-normalized AUCs at different doses under nonlinear kinetics, using incomplete AUC measurements, or interpreting an oral concentration-profile change as a first-pass effect when the perpetrator also changes absorption. AUC ratios summarize total exposure but do not guarantee that peak concentration, trough concentration, or time to peak is correctly predicted. Disagreement in profile shape can signal a problem even when AUC ratios appear reasonable.
Worked Example: Interpreting a Combined Route Pattern
In a hypothetical simulation, the perpetrator-condition oral AUC is 2.40 times baseline, while the IV AUC is 1.60 times baseline. Assume equal doses within each route, linear kinetics, complete AUCs, and unchanged \(F_a\).
The relative change in combined presystemic availability is:
The model therefore implies a 1.50-fold change in \(F_gF_h\), alongside a systemic exposure change corresponding to a 1.60-fold increase in IV AUC. The route ratios alone do not show whether the 1.50-fold presystemic change came from \(F_g\), \(F_h\), or both. A gut-only counterfactual could test whether intestinal inhibition predicts the oral and IV pattern; a hepatic-only counterfactual would test a different joint pattern. Neither site should be declared from these two ratios without the site-specific predictions and supporting assumptions.
Check Your Understanding
Answer each question, then compare with the solutions.
- If \(F_a=0.80\), \(F_g=0.50\), and \(F_h=0.75\), what is systemic oral bioavailability?
- Oral AUC rises 1.8-fold and IV AUC rises 1.2-fold. Assuming unchanged \(F_a\) and linear kinetics, what is the implied fold-change in \(F_gF_h\)? Does this identify the site?
- Why can hepatic CYP inhibition increase oral AUC by more than it increases IV AUC?
- A perpetrator changes oral AUC but not IV AUC. Give one interpretation and one alternative explanation that must be considered.
Solutions. (1) \(F=0.80\times0.50\times0.75=0.300\), or 30.0%. (2) \(1.8/1.2=1.50\), so the product \(F_gF_h\) increased 1.50-fold under the assumptions; this does not distinguish gut from hepatic first pass. (3) Hepatic inhibition can reduce systemic hepatic clearance, increasing IV AUC, while also increasing \(F_h\), which contributes an additional increase to oral AUC. (4) The pattern is consistent with altered presystemic availability, including intestinal CYP inhibition; altered absorption or another oral-specific process is an alternative that should be assessed.